These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 15307815

  • 21. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD.
    Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, Kharitonov SA, Barnes PJ, Ciabattoni G.
    Thorax; 2005 Oct; 60(10):827-33. PubMed ID: 16192367
    [Abstract] [Full Text] [Related]

  • 22. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney.
    Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, Zatz R.
    Kidney Int; 2003 Dec; 64(6):2172-81. PubMed ID: 14633140
    [Abstract] [Full Text] [Related]

  • 23. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.
    Watanabe D, Tanabe A, Naruse M, Morikawa S, Ezaki T, Takano K.
    Hypertens Res; 2009 Sep; 32(9):807-15. PubMed ID: 19662019
    [Abstract] [Full Text] [Related]

  • 24. Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation.
    Trujillo J, Ramírez V, Pérez J, Torre-Villalvazo I, Torres N, Tovar AR, Muñoz RM, Uribe N, Gamba G, Bobadilla NA.
    Am J Physiol Renal Physiol; 2005 Jan; 288(1):F108-16. PubMed ID: 15328066
    [Abstract] [Full Text] [Related]

  • 25. Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression.
    Höcherl K, Kees F, Krämer BK, Kurtz A.
    Kidney Int; 2004 Jun; 65(6):2071-80. PubMed ID: 15149320
    [Abstract] [Full Text] [Related]

  • 26. Renal hemodynamic and histological consequences of diets high in unsaturated fat, protein or sucrose in obese Zucker rats.
    Alavi FK, Zawada ET, Simmons JL.
    Clin Nephrol; 1995 Feb; 43(2):122-30. PubMed ID: 7736674
    [Abstract] [Full Text] [Related]

  • 27. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.
    Zhao X, Li LY.
    Am J Nephrol; 2008 Feb; 28(4):598-606. PubMed ID: 18277067
    [Abstract] [Full Text] [Related]

  • 28. COX-2 and COX-2 enzyme inhibition.
    Conti P.
    Int J Immunopathol Pharmacol; 2003 Feb; 16(2 Suppl):I-II. PubMed ID: 14552697
    [No Abstract] [Full Text] [Related]

  • 29. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
    Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS.
    Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
    [Abstract] [Full Text] [Related]

  • 30. Aerobic training and diabetic nephropathy in the obese Zucker rat.
    Ward KM, Mahan JD, Sherman WM.
    Ann Clin Lab Sci; 1994 Feb; 24(3):266-77. PubMed ID: 8048799
    [Abstract] [Full Text] [Related]

  • 31. Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats.
    Kalonia H, Kumar P, Kumar A, Nehru B.
    Neurotoxicology; 2010 Mar; 31(2):195-203. PubMed ID: 20043943
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Increase of anti-oxidation by exercise in the liver of obese Zucker rats.
    Chang SP, Chen YH, Chang WC, Liu IM, Cheng JT.
    Clin Exp Pharmacol Physiol; 2004 Aug; 31(8):506-11. PubMed ID: 15298542
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin.
    Oana F, Takeda H, Hayakawa K, Matsuzawa A, Akahane S, Isaji M, Akahane M.
    Metabolism; 2005 Aug; 54(8):995-1001. PubMed ID: 16092047
    [Abstract] [Full Text] [Related]

  • 38. Cyclooxygenase-2 and the kidney: functional and pathophysiological implications.
    Harris RC.
    J Hypertens Suppl; 2002 Sep; 20(6):S3-9. PubMed ID: 12683421
    [Abstract] [Full Text] [Related]

  • 39. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
    Kim MS, Wang S, Shen Z, Kochansky CJ, Strauss JR, Franklin RB, Vincent SH.
    Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.